

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings and versions of claims in this application.

Claims 1 to 14. (Cancelled)

15. (Currently Amended) A lipophilic conjugate comprising a peptide coupled to a fatty acid, the peptide or a salt thereof consisting of 2 to ~~14~~ 15 amino acid residues having a net positive charge that is equal or greater than +1 comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid having at least one activity selected from the group consisting of antibacterial, antifungal, and anticancer activity, wherein the activity after conjugation being higher than prior to conjugation, the peptide prior to conjugation of said fatty acid being devoid of or having very weak antibacterial and antifungal activity, wherein the lipophilic conjugate is selected from the group of lipopeptides set forth in SEQ ID NOS: 1 to 38.

Claims 16 to 38. (Cancelled)

39. (Withdrawn, Currently Amended) A method for treating ~~an~~ a bacterial or fungal infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a carrier and, as an active ingredient, a lipophilic conjugate according to claim 15.

40. (Withdrawn) The method according to claim 39, wherein administering the pharmaceutical composition to the subject is selected from topical, intravenous, intraarterial, intramuscular, intraperitoneal, oral, ophthalmic, nasal, vaginal, rectal, and intralesional administration.

41. (Withdrawn) The method according to claim 40, wherein administering the pharmaceutical composition is by topical administration.

42. (Canceled)

43. (Withdrawn, Currently Amended) The method according to claim [[42]] 39, wherein the infection is a bacterial infection.

44. (Withdrawn) The method according to claim 43, wherein the bacterial infection caused by antibiotic-resistant bacteria.

45. (Withdrawn) The method according to claim 44, wherein the antibiotic-resistant bacteria are selected from *Streptococcus pyogenes* and *Staphylococcus aureus*.

46. (Withdrawn, Currently Amended) The method according to claim [[42]] 39, wherein the infection is a fungal infection.

47. (Withdrawn, Currently Amended) The method according to claim 39, wherein the subject has acne, poorly healing skin lesions, or burn wounds or the infection is selected from ~~aene~~, fungal infections of the scalp, fungal infections related to traumatic wounds, bacterial infections related to traumatic wounds, ~~poorly healing skin lesions, and bacterial or fungal eye or ear infections, ear infections, and burn wounds.~~

48. (Withdrawn, Currently Amended) A method for treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a lipophilic conjugate according to claim 15.

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. (Withdrawn, Currently Amended) The method according to claim ~~51~~ 48, wherein the administering of the pharmaceutical composition is into the prostate tumor or adjacent to the prostate tumor.

53. (Withdrawn, Currently Amended) A method for ~~disinfecting~~ reducing bacterial or fungal growth on an object comprising contacting the object with a ~~disinfecting composition,~~ the composition comprising as an active ingredient a lipophilic conjugate according to claim 15.

54. (Withdrawn) The method according to claim 53, wherein the object is selected from the group consisting of tissue culture equipment, tissue culture media, tissue culture incubators, tissue culture hoods, and tissue culture dishes.

55. (Withdrawn) The method according to claim 53, wherein the object is selected from medical and surgical equipment.